(Q34980898)

5 August 2017

1 reference

title

Vascular and cardiac benefits of angiotensin receptor blockers (English)

1 reference

5 August 2017

Ernesto L Schiffrin

1

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

American Journal of Medicine

5 August 2017

published in

1 reference

5 August 2017

volume

113

1 reference

5 August 2017

issue

5

1 reference

5 August 2017

page(s)

409-418

1 reference

AT(1) and AT(2) receptors in the kidney: role in disease and treatment.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Recent progress in angiotensin II type 2 receptor research in the cardiovascular system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Angiotensin II-forming pathways in normal and failing human hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

A novel vascular smooth muscle chymase is upregulated in hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Dual pathway for angiotensin II formation in human internal mammary arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Formulating clinical strategies for angiotensin antagonism: a review of preclinical and clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Tissue angiotensin system in cardiovascular medicine. A paradigm shift?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Reactive oxygen species as mediators of angiotensin II signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Current concepts of the pathogenesis of the acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Angiotensin II type 1 receptor blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Angiotensin type 2 receptors: potential importance in the regulation of blood pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Differential Roles of AT 1 and AT 2 Receptor Subtypes in Vascular Trophic and Phenotypic Changes in Response to Stimulation With Angiotensin II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Angiotensin II type 2 receptor mediates programmed cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Small artery structure in hypertension. Dual processes of remodeling and growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Structure and function of small arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Histology of subcutaneous small arteries from patients with essential hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats : effects of angiotensin receptor antagonism and converting enzyme inhibition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Role of variability in microvascular resistance on fractional flow reserve and coronary blood flow velocity reserve in intermediate coronary lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effect of antihypertensive treatment on response to endothelin of resistance arteries of hypertensive rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Dose-dependent effects of perindopril on blood pressure and small-artery structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effects of low and high doses of fosinopril on the structure and function of resistance arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

The regulation of human vascular smooth muscle extracellular matrix protein production by alpha- and beta-adrenoceptor stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Vascular smooth muscle growth and extracellular matrix deposition: is there a role for the sympathetic nervous system?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

D Allele of the Angiotensin I–Converting Enzyme Is a Major Risk Factor for Restenosis After Coronary Stenting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Angiotensin II type 1 receptor−153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Treatment with irbesartan or atenolol improves endothelial function in essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Blockade of angiotensin II type 1 receptors: effect on carotid and radial artery structure and function in hypertensive humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Blood pressure and inflammation in apparently healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Impact of neuroendocrine activation on coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Valsartan and candesartan can inhibit deteriorating effects of angiotensin II on coronary endothelial function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901241-X

10.1016/S0002-9343(02)01241-X

7 January 2021

Identifiers

DOI

1 reference

5 August 2017

1 reference